Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.64 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631604 | 1.00 | PARP1 (0.64) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630222 | 0.97 | PARP1 (0.62) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630315 | 0.95 | PARP1 (0.60) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL21643633 | 0.93 | PARP1 (0.53) | PARP1HCRTR1HCRTR2 | |
| SCHEMBL21643665 | 0.93 | PARP1 (0.53) | PARP1HCRTR1HCRTR2 | |
| SCHEMBL30578080 | 0.90 | PARP1 (0.51) | PARP1HCRTR1HCRTR2 | |
| SCHEMBL11889787 | 0.87 | PARP1 (0.77) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL21155681 | 0.86 | PARP1 (0.53) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630890 | 0.85 | PARP1 (0.62) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL1048330 | 0.84 | PARP1 (0.54) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420234-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420499-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885TNKS 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.